COST-EFFECTIVENESS OF RECOMBINANT HUMAN FOLLICLE STIMULATING HORMONE BIOSIMILARS IN PORTUGAL

Author(s)

Silverio N, Botica F, Batista AR
Merck SA, Lisboa, Portugal

OBJECTIVES:   To estimate the cost-effectiveness of the original r-hFSH (Gonal-f) when compared with one biosimilar (Ovaleap) using the evidence from a head-to-head registration trial. METHODS:  

Conference/Value in Health Info

2016-10, ISPOR Europe 2016, Vienna, Austria

Value in Health, Vol. 19, No. 7 (November 2016)

Code

PIH18

Topic

Economic Evaluation

Topic Subcategory

Cost-comparison, Effectiveness, Utility, Benefit Analysis

Disease

Reproductive and Sexual Health

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×